down arrow

Alembic Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Drugs
  • ISIN: INE901L01018
  • NSEID: APLLTD
  • BSEID: 533573
INR
840.00
1.5 (0.18%)
BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 87.77 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Alembic Pharmaceuticals Ltd. stock-summary
stock-summary
Alembic Pharmaceuticals Ltd.
Mid Cap
Pharmaceuticals & Drugs
Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The company's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business.
Company Coordinates stock-summary
Company Details
Alembic Road , Vadodara Gujarat : 390003
stock-summary
Tel: 91-0265-2280550
stock-summary
apl.investors@alembic.co.in
Registrar Details
Link Intime India Pvt Ltd., B-102 & B103, Shangrila Complex, First Floor, Opp: HDFC Bank, Near Radhakrishna Char Rasta, Akota, Vadodara
stock-summary Capital Structure
Capital Structure stock-summary
Present Equity Capital
INR 39.31 Cr
Number of Shares
19.66 Cr
Face Value
INR 2.0
Date
Number
of Shares(Cr)
Equity
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
07-Aug-2020
19.66
39.31
8047210
2
Issued to QIBs
20-Sep-2011
18.85
37.70
133515914
2
Scheme of Arrangement
20-Sep-2011
18.85
37.70
133515914
2
Scheme of Arrangement
16-Jun-2010
5.5
11.00
55000000
2
Subscription to the Memorandum of Association
16-Jun-2010
5.5
11.00
55000000
2
Subscription to the Memorandum of Association
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 21 Schemes (8.96%)

FIIs

Held by 164 FIIs (4.17%)

Promoter with highest holding

Nirayu Limited (35.63%)

Highest Public shareholder

Dsp Midcap Fund (4.38%)

Individual Investors Holdings

7.26%

stock-summary Board of Directors
stock-summary
stock-summary
Management
Designation
Remuneration
Chirayu R Amin
Chairman & CEO
8.8 cr
Pranav N Parikh
Independent Director
18.7 lacs
K G Ramanathan
Independent Director
19.1 lacs
Paresh Saraiya
Independent Director
18.7 lacs
Rajkumar Baheti
Director (Finance) & CFO
5.69 cr
Pranav Amin
Managing Director
12.22 cr
Shaunak Amin
Managing Director
12.22 cr
Archana Hingorani
Independent Director
18.3 lacs
Ashok Barat
Independent Director
18.2 lacs
Manisha Saraf
Company Sec. & Compli. Officer
0
Jai S Diwanji
Independent Director
0
stock-recommendationRaw Materials
Raw Materials Dashboard stock-summary
Raw Materials
Amount(Rs Cr)
% of RM Cost
 
Icon
No Data Available
stock-recommendation Finished Goods
Finished Goods Dashboard stock-summary
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceutical Goods
3,533.84
96.55%
Export Incentives
88.18
2.41%
Royalty
30.67
0.84%
 
96.55
Pharmaceutical Goods
3.45
Pharmaceutical Goods
2.41
Export Incentives
97.59
Export Incentives
0.84
Royalty
99.16
Royalty
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,693 Cr
(Quarterly Results - Dec 2024)
Net Profit:
138 Cr
stock-summary
Industry

Pharmaceuticals & Drugs

stock-summary
Market cap

INR 16,511 Cr (Mid Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

1.31%

stock-summary
Debt Equity

0.19

stock-summary
Return on Equity

13.01%

stock-summary
Price to Book

3.37